We’d love to hear your feedback on this activity. It helps us to continually improve our products.
We had the great pleasure to meet with Jessica Ailani (MedStar Georgetown Headache Center, Georgetown, WA, USA) to discuss the Phase 3 ADVANCE study (NCT03777059) results investigating atogepant for the treatment of migraine. The abstract entitled: ‘Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Preventive Treatment of Migraine‘ […]
We had the great pleasure to meet with Jessica Ailani (MedStar Georgetown Headache Center, Georgetown, WA, USA) to discuss the use of gepants and their impact on the treatment landscape for migraines. The abstract entitled: ‘Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Preventive Treatment of Migraine‘ was […]
We were delighted to speak with Michael Sperling (Thomas Jefferson University, Philadelphia, PA, USA) to discuss the recent post-hoc analysis of cenobamate for uncontrolled focal seizures, and its intended place in the treatment landscape for epilepsy. The abstract entitled: ‘Efficacy of Cenobamate for Uncontrolled Focal Seizures: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study’ […]
It was a great pleasure to meet with Michael Weiner (University of California, San Francisco, CA, USA), the Principal Investigator for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), to discuss the initiative’s aims, design and future developments. The abstract entitled ‘Validating Plasma Tests for Amyloid, Tau, and Neurodegeneration Using the Alzheimer’s Disease Neuroimaging Initiative (ADNI)’ was […]
It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss the phase 2 trial investigating ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The […]
It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The 15th International Conference for Alzheimer’s […]
touchNEUROLOGY had the great pleasure of speaking with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA) to discuss the phase 2 MCLENA-1 clinical trial rationale, assessing lenalidomide in patients with mild cognitive impairment due to Alzheimer’s Disease. The abstract entitled ‘Rationale for the MCLENA-1: A Phase II Clinical Trial for the Assessment […]
We had the pleasure of speaking with Tanya Simuni (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the use of venglustat in the treatment of patients with Parkinson’s Disease, and the Phase 2 MOVES-PD study results. Part 1 of our discussion can be viewed here. The abstract entitled ‘Venglustat in Parkinson’s Disease […]
We caught up with Tanya Simuni (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the use of venglustat in the treatment of patients with Parkinson’s Disease, and the Phase 2 MOVES-PD study results. Part 2 of our discussion can be viewed here. The abstract entitled ‘Venglustat in Parkinson’s Disease Patients with a […]
Get the latest clinical insights from touchNEUROLOGY